Tag: CRISPR
ATCC Awarded Two Projects from the USDA Including the Creation of ARS Resources Collection...
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded two projects, with a combined value of $385,000, by the United States Department of Agriculture (USDA) to support its Agricultural Research Service (ARS) agency over...
Broad And Sanger Reproduce CRISPR-Cas9 Genetic Knock-Out Screens In 725 Cancer Cell Line Models
A comprehensive map of genes necessary for cancer survival
is one step closer, following the validation of the two largest CRISPR-Cas9
genetic screens in 725 cancer models across 25 different cancer types.
Scientists at the Wellcome Sanger Institute and the Broad Institute...
CRISPR Therapeutics And Vertex Release Interim Phase I Data On CRISPR/Cas9 Gene-Editing Therapy
CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated have
announced positive, interim data from the first two patients with severe
hemoglobinopathies treated with the investigational CRISPR/Cas9 gene-editing
therapy CTX001 in ongoing Phase 1/2 clinical trials. One patient with
transfusion-dependent beta thalassemia (TDT) received CTX001 in...
Biobanking Science: CRISPR Gene Editing to Treat Human Disease
This year has seen a flurry of good news about CRISPR gene editing clinical trials in human patients. CRISPR-Cas 9 is a gene editing tool capable of providing specific changes to genes in a wide range of animal models....
CRISPR Therapeutics And ViaCyte Collaborate To Create Universal Stem Cell Therapies For Diabetes
CRISPR Therapeutics and ViaCyte, Inc. have announced a collaboration focused on the discovery, development, and commercialization of gene-edited allogeneic stem cell therapies for the treatment of diabetes. ViaCyte is a privately-held regenerative medicine company, founded in 1999, headquartered San Diego,...
Cell Therapy – New Method To Reprogram T-cells Without Viral Vectors Developed At UCSF
A new method has been developed, primarily by University of California San Francisco (UCSF) researcher Theo Roth of Alex Marson’s laboratory, to introduce gene editing CRISPR technology into T-cells without the use of viral vectors. The method was published...
